Financial Data and Key Metrics Changes - Net revenues for Q2 2023 were $10.9 million, representing a 6% increase year-over-year and an 18% increase sequentially from Q1 2023 [7][12][64] - Operating expenses decreased to $10.9 million from $12.1 million in the prior year period, with year-to-date expenses totaling $21.6 million [65] - Net income for the quarter was $0.9 million, with adjusted earnings of $2.3 million or $0.16 per share, showing significant improvement over last year [65][66] Business Line Data and Key Metrics Changes - Vibativ sales increased by 35% year-over-year, with ongoing initiatives to enhance brand performance [13] - Kristalose sales rose by 15% year-over-year, continuing to be the largest selling product [41] - Caldolor sales were up 3%, with expectations for special Medicare reimbursement starting in 2025 [10][42] - Sancuso underperformed due to sales deductions related to returns and rebates during its transition [42] Market Data and Key Metrics Changes - The transition of RediTrex to Nordic Pharma was largely completed as of July 1, 2023 [9][21] - The company is exploring international market opportunities, with partners in South Korea and China seeking approval for Vibativ [23][52] Company Strategy and Development Direction - The company is focused on maximizing the potential of its commercial brands, progressing its pipeline, and pursuing select acquisitions [70] - An expanded oncology sales division was launched to support the Sancuso product and improve its market presence [8][44] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the gradual improvement in the operating environment post-pandemic and highlighted positive developments in the business [7] - The company is encouraged by the growth in Kristalose and Vibativ, while also noting the steady performance of Caldolor [59] Other Important Information - The company received $3 million in refunds from the FDA for prescription drug fees, recorded as other income [40][67] - Cumberland continues to hold over $53 million in tax net operating loss carryforwards [68] Q&A Session Summary - No specific questions or answers were documented in the provided content, indicating a focus on the presentation rather than a detailed Q&A session [71][72]

In addition to the other information set forth in this quarterly report, an investor should consider the risk factors included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022. Inflation rates have increased recently to levels not seen in decades. If our costs, in particular costs related to clinical trial expenses and/or employee-related expenses, were to become subject to significant inflationary pressures, it may adversely impact our business, operating results and financi ...

Financial Performance - Net revenues for the first quarter of 2023 were $9.2 million, consistent with the fourth quarter of 2022, but down from the same quarter last year due to delays in international shipments and an unusual number of product returns [7][14][43] - The company reported a net income of $0.2 million for the quarter, with adjusted earnings of $1.7 million or $0.11 per share [50][43] - Total assets at the end of March 2023 were $89 million, with total liabilities of $53 million and total shareholders' equity of $36 million [16][43] Business Line Performance - Net revenues by product included $4.3 million for Kristalose, $1.9 million for Sancuso, $1.8 million for Vibativ, and $0.9 million for Caldolor [14] - Vibativ has delivered a total cash contribution of $33 million since its acquisition, generating a return on the $25 million investment [15] - Sancuso has provided a total cash contribution of approximately $11 million since shipping began early last year [51] Market Developments - The state of New York has added Kristalose to their Medicaid formulary, prompting a special initiative to increase market presence [29] - The company is working with international partners to register brands in various countries, including Caldolor in Mexico and Vibativ in Saudi Arabia [12][48] Strategic Direction and Industry Competition - The company is focused on expanding its portfolio of FDA-approved products and enhancing its marketing strategies for Vibativ [10][45] - The recent "no pain" legislation is expected to positively impact Medicare reimbursement for Caldolor, scheduled to take effect in early 2025 [5][41] Management Commentary on Operating Environment - The management highlighted challenges such as workforce shortages, supply chain interruptions, rising interest rates, and the recent banking crisis, but emphasized the team's dedication to delivering products and advancing new medicines [24] - The company received a nearly $2 million refund from the FDA due to a waiver granted for drug program fees, which will be used to advance clinical programs [25] Other Important Information - The company continues to hold over $57 million in tax net operating loss carryforwards, primarily from prior stock option exercises [52] - The transition of RediTrex to Nordic Pharma is underway, with marketing authorization transferred and commercial responsibilities set to conclude by the end of June [42] Q&A Session Summary Question: What are the expectations regarding the reimbursement for Caldolor under the new legislation? - The "no pain" legislation is expected to provide separate and more favorable reimbursement for Caldolor, with guidelines anticipated in 2024 [41] Question: How is the company addressing the challenges in the operating environment? - The management acknowledged the challenges but emphasized the team's commitment to overcoming these headwinds and continuing to deliver FDA-approved products [24] Question: What is the status of the company's international registration efforts? - The company is actively supporting international partners in registering its brands, with ongoing efforts in Mexico and Saudi Arabia [12][48]

Joint Venture Agreement (8) OTHER INCOME Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment received related to RediTrex, do not meet the criteria for accounting ...

Financial Position and Assets - As of December 31, 2022, intangible assets related to acquisitions represented approximately 33% of total assets [286]. - The aggregate market value of common stock held by non-affiliates as of June 30, 2022, was $17.3 million [428]. - The number of shares of the registrant's Common Stock outstanding as of March 7, 2023, was 14,395,401 [428]. Capital Requirements and Funding - The company may need to raise additional funds to meet capital requirements for business operations and new pharmaceutical product development, which could lead to shareholder dilution [287]. - The company anticipates increased expenditures in drug discovery and development, particularly for clinical trials prior to regulatory approval [288]. - The company intends to continue significant investments in drug discovery and development, which may lead to future losses [314]. Corporate Governance and Control - As of December 31, 2022, officers and directors control approximately 41.81% of common stock, potentially influencing corporate decisions [291]. - The company has never paid cash dividends on its capital stock, indicating a focus on reinvestment [297]. Market Risks and Stock Performance - The market price of the company's common stock may fluctuate substantially, influenced by analyst reports and market conditions [292]. - The company may face challenges in maintaining its NASDAQ listing if it fails to meet minimum requirements, which could negatively impact stock liquidity and market price [294]. Financial Management and Risk Exposure - The company is exposed to market risk related to changes in interest rates on cash deposits and revolving credit facilities, focusing on principal preservation and liquidity [423]. - A portion of the company's research and development is performed abroad, exposing it to foreign currency risk [425]. - The company does not utilize derivative financial instruments to manage exposure to interest rate changes [423]. - The company emphasizes maximizing interest income through low-risk investments [423]. Regulatory and Reporting Status - The company is classified as a non-accelerated filer and a smaller reporting company under the Exchange Act [427]. - The company is not a well-known seasoned issuer as defined in Rule 405 of the Securities Act [426]. Forward-Looking Statements and Uncertainties - The company has made forward-looking statements regarding its future operations, which are subject to various risks and uncertainties [424]. - The company may incur significant losses in the future and may not achieve or maintain profitability due to uncertainties in generating commercially successful drug products [289]. Covenants and Obligations - The Revolving Credit Agreement imposes restrictive covenants that could adversely affect business operations if not complied with [298]. - The sum of individual amounts in the contractual cash obligations may not agree due to rounding [421].

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A.J. Kazimi - CEO Todd Anthony - VP, Organizational Development John Hamm - CFO Conference Call Participants Operator Good afternoon, and welcome to Cumberland Pharmaceuticals' 2022 Financial Report and Company Update. This call is being recorded at Cumberland's request and will be archived on the company's website for one year from toda ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-33637 Cumberland Pharmaceuticals Inc. (Exact Name of Registrant as Specified In Its Charter) Tennessee 62-1765329 (State or ...

Financial Data and Key Metrics Changes - Cumberland Pharmaceuticals reported net revenues of $11.4 million for Q3 2022, a 41% increase from $8.1 million in Q3 2021 [28] - Year-to-date net revenues reached $32.9 million, up 19% from $27.7 million in the same period last year [30] - Adjusted earnings for Q3 were $1.4 million or $0.10 per share, a significant improvement from an adjusted loss of $327,000 in the previous year [32] - Total cash flow from operations was $5.6 million, a 28% increase over the first nine months of 2021 [33] Business Line Data and Key Metrics Changes - Revenue contributions for Q3 2022 included $4 million from Sancuso, $3.9 million from Kristalose, $1.9 million from Vibativ, and $0.9 million from Caldolor [29] - The addition of Sancuso significantly impacted overall revenue growth, contributing to a combined revenue increase of 41% year-over-year [15] Market Data and Key Metrics Changes - The company is experiencing staffing shortages at hospitals and clinics, affecting patient procedures and facility visits, but is seeing a return to a more typical selling environment [10] - International partnerships are being established, such as with Tabuk Pharmaceutical for Vibativ in the Middle East and a new agreement for Caldolor in Mexico [46][45] Company Strategy and Development Direction - Cumberland is focused on maximizing the potential of its commercial brands, progressing its pipeline, and pursuing new acquisitions, particularly emphasizing the positive impact of Sancuso [49] - The company is sponsoring three Phase II clinical programs for its ifetroban product candidate, targeting unmet medical needs in various diseases [41] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving double-digit revenue growth for 2022, supported by new products and an improved selling environment [51] - The company is confident in its new headquarters' role in future success and its ability to better serve international customers [50] Other Important Information - Cumberland's total assets grew to $91 million by the end of Q3 2022, with total liabilities at $53 million [15][37] - The company continues to hold over $56 million in net operating loss carryforwards, primarily from prior stock option exercises [40] Q&A Session Summary - The call concluded without specific questions being recorded, indicating a preference for private discussions with management for further inquiries [52][53]

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q2 2022 Results Conference Call August 9, 2022 4:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A.J. Kazimi - Chief Executive Officer Todd Anthony - Vice President, Organizational Development John Hamm - Chief Financial Officer Operator Good afternoon, and welcome to Cumberland Pharmaceuticals Second Quarter 2022 Financial Report and Company Update. This call is being recorded at the company's request and will be archived on Cumber ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-33637 Cumberland Pharmaceuticals Inc. (Exact Name of Registrant as Specified In Its Charter) Tennessee 62-1765329 (State or Othe ...